![]() Relatlimab-nivolumab combination showed no new safety signals. Relatlimab–nivolumab also had the PFS benefit over nivolumab in prespecified subgroups. ![]() The separation of the PFS curves occurred at the initial postbaseline assessment at approximately 12 weeks and was sustained thereafter. ![]() Blinded independent assessment of the primary endpoint showed that progression-free survival (PFS) was longer with relatlimab–nivolumab combination than with single agent nivolumab. A phase II/III, RELATIVITY-047, global, double-blind, randomised study evaluated dual inhibition of LAG-3 and PD-1 using a new combination of LAG-3–blocking antibody relatlimab and PD-1–blocking antibody nivolumab, as compared with nivolumab alone.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |